Parkinson's disease is a progressive neurodegenerative disorder which often results in disability. If pharmacological agents could slow the progression of disease early disability, job loss, and nursing home placement might be delayed. This clinical trial utilizing a randomized, double blind design will evaluate the efficacyof one or more pharmacological agents for slowing progression of Parkinson's disease and will determine the toxicity and tolerability of these agents. The trial will continue to enroll patients with Parkinson's disease who recently started dopaminergic therapy, will be able to detect small treatment effects, will incorporate innovative sample follow-up methods, and will be able to distinguish neuroprotective effects from occult symptomatic benefits. This center will is one of 42 clinical centers designated to continue to participate in this study.
For people with Parkinson's disease, there is no greater priority than to find new approaches that will delay disease progression. The NET-PD project has been a special and unique source of encouragement to people with PD since it is dedicated to the discovery of strategies for disease modification and employs novel approaches to identify promising agents and to investigate their potential.
|Wills, Anne-Marie A; Elm, Jordan J; Ye, Rong et al. (2016) Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord 33:127-133|
|Wills, Anne-Marie A; Pérez, Adriana; Wang, Jue et al. (2016) Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1 JAMA Neurol 73:321-8|
|Elm, Jordan J; NINDS NET-PD Investigators (2012) Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord 27:1513-21|
|Mauldin, Patrick D; Guimaraes, Paulo; Albin, Roger L et al. (2008) Optimal frequency for measuring health care resource utilization in Parkinson's disease using participant recall: the FS-TOO resource utilization substudy. Clin Ther 30:1553-7|